a Department of Orthopedics, Academy of Orthopedics of Guangdong Province, the Third Affiliated Hospital, Southern Medical University , Guangzhou , China.
b Department of Environmental Health, School of Public Health, Guangxi Medical University , Nanning , China.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1859-1866. doi: 10.1080/21691401.2019.1611593.
The purpose of our research was to explore potential value of lncRNA-BC050642 in osteosarcoma origination and prognosis. In this study, the tissue specimens were collected from 97 osteosarcoma patients and 97 age-matched healthy controls. Besides, human osteosarcoma cell lines U2OS and normal osteoblastic cell line hFOB1.19 were selected for experiments . lncRNA-BC050642 levels were measured through quantitative real-time polymerase chain reaction (qRT-PCR). Relative expression of the gene was determined via ELISA analysis test was implemented to appraise possible relationship between BC050642 level and clinicopathological features. Cell proliferation assay, plate colony formation assay, and cell apoptosis assay were adopted to analyze the influence of BC050642 on tumor development. Besides, prognostic value of BC050642 was estimated using Kaplan-Meier and cox regression analysis. BC050642 levels showed distinctive increases in osteosarcoma tissues and cell lines compared with controls. And expression was down-regulated in osteosarcoma. There was a negative correlation between the expressions of BC050642 and . BC050642 expression was proved to be significantly correlated with Ennking and histological type. Up-regulated BC050642 could promote cell proliferation, induce colony formation and meanwhile inhibit cell apoptosis. BC050642 is up-regulated in osteosarcma and its over-expression promotes tumor development via down-regulating the expression of . It also may be an independent prognostic biomarker for osteosarcoma.
我们的研究目的是探索 lncRNA-BC050642 在骨肉瘤发生和预后中的潜在价值。在这项研究中，我们收集了 97 例骨肉瘤患者和 97 例年龄匹配的健康对照者的组织标本。此外，我们选择了人骨肉瘤细胞系 U2OS 和正常成骨细胞系 hFOB1.19 进行实验。通过定量实时聚合酶链反应(qRT-PCR)测量 lncRNA-BC050642 水平。通过酶联免疫吸附试验(ELISA)分析评估 BC050642 水平与临床病理特征之间的可能关系，从而确定基因的相对表达。采用细胞增殖试验、平板集落形成试验和细胞凋亡试验分析 BC050642 对肿瘤发展的影响。此外，采用 Kaplan-Meier 和 Cox 回归分析估计 BC050642 的预后价值。BC050642 水平在骨肉瘤组织和细胞系中明显升高，与对照组相比。在骨肉瘤中表达下调。BC050642 的表达与呈负相关。BC050642 的表达与 Ennking 分级和组织学类型显著相关。上调的 BC050642 可以促进细胞增殖，诱导集落形成，同时抑制细胞凋亡。BC050642 在骨肉瘤中上调，其过表达通过下调的表达促进肿瘤发展。它也可能是骨肉瘤的一个独立预后生物标志物。
